Document is current
Any future updates will be listed below
-
Authors
Jiménez-Pastor, Jose M.
Morales-Cané, Ignacio
Rodríguez-Cortés, Francisco J.
López-Coleto, Luna
Valverde-León, Rocío
Arévalo-Buitrago, Pedro
Medina-Valverde, María J.
De la Fuente-Martos, Carmen
Acuña-Castroviejo, Darío
Meira e Cruz, Miguel
Luque, Raúl M.
Sarmento-Cabral, André
López-Soto, Pablo J. https://orcid.org/0000-0002-1046-6686
-
Funding
Funding for this research was provided by:
Consejería de Salud y Consumo, Junta de Andalucía (PIGE-0462-2019)
Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (UCO_FEDER 1381293-R)
- License Information
-
More Information
Article History
Received: 14 November 2024
Accepted: 5 February 2025
First Online: 17 February 2025
Declarations
:
: This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Reina Sofia University Hospital Ethics Committee (Act nº 277; ref. 3878). Patients older than 18 years were provided with an information sheet before inclusion in the study, and informed consent was obtained from all participants. If patients could not consent due to their clinical condition, permission was obtained from their families.
: Not applicable.
: Darío Acuña-Castroviejo is a confounder of Pharmamel, which has developed therapeutic uses for melatonin. Miguel Meira e Cruz is a member of the BodiMetrics medical advisory board. All authors have no conflicts of interest to disclose.
